Nursing 250 – Endocrine Disorder Assignment
Nursing 250 – Endocrine Disorder Assignment
Nursing care of a child with an endocrine disorder. Jalissa Twyman, 8 years old, was admitted to the pediatric intensive care unit with a closed head trauma after been involved in a bicycle/motor vehicle accident. Jalissa is unconscious. The nurses caring for Jalissa document a weight loss of 1.82 kg over a 24- hour period, decreased skin turgor, and dry mucus membranes. Urine output for the same 24-hour period is 3.5 L/m2. (a) What further assessments should the nurse perform on Jalissa? (b) What laboratory tests would the nurse expect to be performed on Jalissa? (c) What nursing interventions should be done for Jalissa?
a. What further assessments should the nurse perform on Jalissa?
b. What laboratory tests would the nurse expect to be performed on Jalissa?
Struggling to meet your deadline ?
Get assistance on
Nursing 250 – Endocrine Disorder Assignment
done on time by medical experts. Don’t wait – ORDER NOW!
c. What nursing interventions should be done for Jalissa?
Other Answers
(a) Further assessments
- Tachycardia
- Urine concentration
- Increased respiratory rate
(b) Lab Tests
- UA
- Fluid deprivation test
- CT scan, MRI, or ultrasound of kidneys and the skull
- Serum sodium
- Serum osmolarity
(c) Nursing Interventions
- Promoting hydration
- Administration of ordered medications
- Maintenance of nasogastric feeding tube
- Comfort measures
- Frequent monitoring of vital signs
- Emotional support for Jalissa and her family
- Pain assessment
It’s 8 p.m. on Tina Jones’ first day as a patient here at Shadow General Hospital. Your role in this simulation is that of a healthcare provider who will perform a full abdominal exam on Ms. Jones. She’s spent the whole day in bed, so you will want to determine
whether she has full abdominal function and if bed rest has impacted her gastrointestinal health.
In your interview with Ms. Jones, you will ask about her inputs and outputs (I’s and O’s) and the overall health of her abdominal system so that you can identify any issues and document findings accurately. If you discover any disease states, ask about symptoms
and the patient’s experiences of them.
DISEASES OF MANY GLANDS
Multiple gland failure
This is caused by autoimmune disease as detailed. Commonest are the associations of primary hypothyroidism and type 1 diabetes, and either of these with Addison’s disease or pernicious anaemia.
Multiple endocrine neoplasia
This is the name given to the simultaneous or metachronous recurrence of tumours involving a number of endocrine glands. They are inherited in an autosomal dominant manner and are thought to arise from the expression of a recessive oncogenic mutation, which has now been isolated.
Affected persons may pass on the mutation to their offspring in the germ cell, but for the disease to become evident a somatic mutation must also occur, e.g. deletion or loss of a normal homologous chromosome. The defect in MEN 1 is on the long arm of chromosome 11 near an area containing a number of oncogenes that encode for proteins with fibroblastic growth factor activity. The gene for MEN 2a is on chromosome 10 close to the retinol binding gene.
Screening unaffected members of a family shows that a significant number of affected individuals are unrecognized, especially with hypercalcaemia.
THE SYNTHESIS AND METABOLISM OF CATECHOLAMINES. (OMT, CATECHOL-OMETHYL TRANSFERASE; MAL, MONOAMINE OXIDASE.
MANAGEMENT
is surgical.
TYPE 1. All four parathyroid glands are removed (as all may be involved) followed by vitamin D (1,25- dihydrocalciferol) replacement therapy. Pancreatic tumours are often multiple and recurrence after partial pancreatectomy is invariable. Other tumours are treated surgically if necessary.
TYPE 2. Tumours may also be recurrent or bilateral and a careful follow-up is necessary.
Symptoms
Anxiety or panic attacks
Palpitations
Tremor
Sweating
Headache
Flushing
Nausea and/or vomiting
Weight loss
Constipation or diarrhoea
Raynaud’s phenomenon
Chest pain
Polyuria/nocturia
Signs
Hypertension-intermittent or constant
Tachycardia plus arrhythmias
Bradycardia
Orthostatic hypotension
Pallor or flushing
Glycosuria
Fever
(Signs of hypertensive damage)
Screening
A careful family history should first be taken. If negative, it does not exclude involvement and it may need repeating at regular (1-5 year) intervals.
1 Type 1. Fasting calcium estimation (if elevated, look for other manifestations of MEN 1). 2 Type 2
(a) Medullary carcinoma of thyroid (MCT). Pentagastrin and calcium infusion test with measurement of calcitonin to pick up ‘C’ cell hyperplasia: doubling of the calcitonin level is abnormal.
(b) Phaeochromocytoma. VMA and metanephrine estimations.
MULTIPLE ENDOCRINE NEOPLASIA SYNDROMES.
ECTOPIC HORMONE SECRETION
This terminology refers to hormone synthesis, and normally secretion, from a neoplastic non-endocrine cell, most usually seen in tumours that have some degree of embryological resemblance to specialist endocrine cells. Multiple theories have been advanced to explain the occurrence. The clinical effects may be those of the hor- .mone produced, with or without manifestations of systemic malignancy.
The commonest situations seen are:
HYPERCALCAEMIA OF MALIGNANT DISEASE, often from squamous cell tumours of lung and breast, often with bone metastases. It is mediated by many different factors, but very rarely by PTH itself; a PTH-related protein (PTHrP) with considerable sequence homology has recently been isolated and appears to be the most frequent cause.
SIAD H. Again, this is commonest from a primary lung tumour. ECTOPIC ACTH SYNDROME. Small-cell carcinoma of the lung, carcinoid tumours and medullary thyroid carcinomas are the commonest causes.
PRODUCTION OF INSULIN-LIKE ACTIVITY may result in hypoglycaemia.
ENDOCRINE TREATMENT OF OTHER MALIGNANCIES
Endocrine forms of treatment for malignancy have been used for many years, for example oophorectomy for breast cancer and orchidectomy for prostatic malignancy. Newer more acceptable therapies include the antioestrogen tamoxifen for breast carcinoma and the LHRH analogues, buserelin and goserelin, for prostatic cancer.